Leukocyte News and Research

RSS

Nationwide Children's Hospital investigator to continue research on heparin-binding EGF

Gail Besner, MD, principal investigator in the Center for Perinatal Research in The Research Institute at Nationwide Children's Hospital, has been awarded a 4-year RO1 grant from the National Institutes of Health to continue her work on heparin-binding EGF-like growth factor (HB-EGF) and intestinal ischemia-reperfusion injury.

24 Oct 2011

Preclinical data from Teva's COPAXONE study on multiple sclerosis

Teva Pharmaceutical Industries Ltd. today announced preclinical data demonstrating reparative and neuroprotective effects of treatment with COPAXONE (glatiramer acetate injection) in experimental autoimmune encephalomyelitis (EAE) models.

21 Oct 2011

ApoPharma receives FDA approval for Ferriprox to treat transfusional iron overload

The U.S. Food and Drug Administration today approved Ferriprox (deferiprone) to treat patients with iron overload due to blood transfusions in patients with thalassemia, a genetic blood disorder that causes anemia, who had an inadequate response to prior chelation therapy.

15 Oct 2011

Engineered HBLs could prevent deadly allergic reactions

Researchers from the University of Notre Dame have announced a breakthrough approach to allergy treatment that inhibits food allergies, drug allergies, and asthmatic reactions without suppressing a sufferer's entire immunological system.

14 Oct 2011

Peanut allergy could be switched off

Now researchers may have discovered how to switch off food allergies. Researchers from Northwestern University found a way to tweak the immune system so that it doesn’t react when foods like peanuts and eggs are encountered – in mice.

12 Oct 2011

Vitamin D plays an essential role in the body's fight against TB

Not just important for building strong bones, an international team of scientists has found that vitamin D also plays an essential role in the body's fight against infections such as tuberculosis.

12 Oct 2011

Tantalizing glimmers about roles of CCR2 gene, Th17 cell and a missing monocyte

An estimated 1.3 million people in the United States suffer from rheumatoid arthritis. The causes behind this chronic disease — which can exhibit itself as pain, swelling, stiffness, deformation, and loss of function in the joints — have eluded scientists for centuries. A new study by UNC researchers offers tantalizing glimmers about the roles of a gene called CCR2, an immune system cell called Th17 cell, and a missing monocyte.

11 Oct 2011

New mechanism to enhance restoration of blood flow in ischemic diseases

In Nature, VIB-K.U.Leuven researchers describe a new mechanism to enhance the restoration of the blood flow in ischemic diseases, which are among the leading causes of death worldwide.

11 Oct 2011

Statins hold promise against traumatic brain injury

Older patients who happened to have been taking cholesterol-lowering statin drugs when admitted to the hospital with serious head injuries were 76 percent more likely to survive than those not taking the drugs, according to results of a Johns Hopkins study.

11 Oct 2011

New siRNA treatment reduces damaging inflammation in animals models of several disorders

Massachusetts General Hospital (MGH) researchers - along with collaborators from Massachusetts Institute of Technology (MIT) and Alnylam Pharmaceuticals - have found a way to block, in an animal model, the damaging inflammation that contributes to many disease conditions.

10 Oct 2011

Researchers identify cellular pathway to potentially block disease-inducing inflammation

Researchers have discovered a cellular pathway that promotes inflammation in diseases like asthma, rheumatoid arthritis, psoriasis, inflammatory bowel disease, and multiple sclerosis. Understanding the details of this pathway may provide opportunities for tailored treatments of inflammatory and autoimmune diseases.

10 Oct 2011

CEL-SCI closes previously announced registered direct offering

CEL-SCI Corporation announced today that it has closed its previously announced registered direct offering for the sale of (i) 13,333,334 shares of its common stock at a price per share of $0.30 and (ii) warrants to purchase up to 12,000,000 shares of CEL-SCI Corporation's common stock at a purchase price of $0.40. The warrants may be exercised at any time prior to October 6, 2014.

7 Oct 2011

Researchers discover cell differentiation mechanism

Researchers from the Haematopoietic Differentiation and Stem Cell Biology group at the Centre for Genomic Regulation (CRG), have described one of the mechanisms by which a cell (from the skin, for example) can be converted into another which is completely different.

4 Oct 2011

La Jolla Institute scientist identifies previously unknown T cell interaction

Most of the time, the immune system is the body's protector, warding off invading viruses and bacteria before they can lead to infection and disease. But in autoimmune diseases, the immune system does an about face, turning on the body and attacking normal cells.

3 Oct 2011

Study demonstrates how the intestine maintains 'immune tolerance' under healthy conditions

Imagine a single drug that would treat most, if not all, autoimmune disorders, such as asthma, inflammatory bowel disease, and Lupus. That might not be so hard to do thanks to a team of researchers who have discovered a molecule normally used by the body to prevent unnecessary immune reactions.

30 Sep 2011

Patients with chronic hepatitis C less likely to take medications over time

Patients being treated for chronic hepatitis C become less likely to take their medications over time, according to a new study from the Perelman School of Medicine at the University of Pennsylvania.

30 Sep 2011

Immunotherapeutics for treatment of metastatic melanoma

A new cancer research program at Loyola University Chicago Stritch School of Medicine will develop therapies designed to turn patients' own immune systems into potent weapons against cancer.

30 Sep 2011

G-Zero receives NIAID's Phase II Small Business Innovation Research Grant

G-Zero Therapeutics, an RTP company started in 2008 based on technologies from the University of North Carolina at Chapel Hill, has been awarded a $3 million Phase II Small Business Innovation Research Grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

30 Sep 2011

Study provides insight into earliest stages of some cancers

A novel technique that enables scientists to measure and document tumor-inducing changes in DNA is providing new insight into the earliest events involved in the formation of leukemias, lymphomas and sarcomas, and could potentially lead to the discovery of ways to stop those events.

30 Sep 2011